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Objectives This study compared prognoses of myocardial infarction related to percutaneous coronary intervention (PCI, pro-
cedural MI) using increasing creatine kinase-myocardial band (CK-MB) thresholds with spontaneous MI.
Background Procedural MI usually is defined by a CK-MB elevation of more than 3 times the upper limit of normal (ULN), but
higher thresholds have been proposed.
Methods Patients from the EARLY-ACS (Early Glycoprotein IIb/IIIa Inhibition in Non–ST-Segment Elevation Acute Coronary
Syndrome) study and the SYNERGY (Superior Yield of the New strategy of Enoxaparin, Revascularization and
GlYcoprotein IIb/IIIa inhibitors) study treated with PCI were included. The primary end point was 1-year all-cause
mortality from 24 h after PCI. To determine an enzymatic threshold for procedural MI with a prognosis similar to
that of spontaneous MI, we redefined procedural MI using increasing CK-MB thresholds and compared corre-
sponding hazard ratios with those of spontaneous MI (CK-MB more than twice the ULN). Hazard ratios for mortal-
ity for procedural and spontaneous MI were calculated using Cox proportional hazards regression and Global
Registry of Acute Cardiac Events covariates for risk adjustment.
Results Nine thousand eighty-seven patients who underwent PCI (46.8%) were included; 773 procedural MI and 239 spontaneous
MI occurred within 30 days. Adjusted hazard ratios for 1-year death were 1.39 (95% confidence interval [CI]: 1.01 to 1.89)
for procedural MI and 5.37 (95% CI: 3.90 to 7.38) for spontaneous MI. The CK-MB threshold for procedural MI that
achieved the same prognosis as spontaneous MI was 27.7 times the ULN (95% CI: 13.9 to 58.4), but this differed between
the SYNERGY study (57.9 times the ULN, 95% CI: 17.9 to 63.6) and the EARLY-ACS study (20.4 times the ULN, 95% CI:
5.16 to 24.2). Of all procedural MI, 49 (6%) had CK-MB elevations of 27.7 or more times the ULN.
Conclusions The current enzymatic definition of procedural MI (CK-MB more than 3 times the ULN) used in clinical trials is
less strongly associated with death than that of spontaneous MI. Procedural MI achieves similar prognosis for
1-year mortality when much higher CK-MB thresholds are applied. (J Am Coll Cardiol 2012;60:2296–304)
© 2012 by the American College of Cardiology Foundation
Published by Elsevier Inc. http://dx.doi.org/10.1016/j.jacc.2012.09.005Company and Daiichi Sankyo. Dr. Califf has received research grants from
Amylin, J&J-Scios, Merck/Schering Plough, Novartis, and the Bristol-Myers
Squibb Foundation; is a consultant for J&J-Scios, Novartis, Bayer, Roche, Pfizer,
and the Bristol-Myers Squibb Foundation; and has equity in NITROX LLC. Dr.
Newby has received research grants from Amylin, AstraZeneca, Bristol-Myers
Squibb, diaDexus, Eli Lilly & Co., GlaxoSmithKline, Merck, Inc., Murdock
Study, NHLBI, Regado Biosciences, Inc., Roche, and Schering-Plough; and is a
consultant for AstraZeneca, Daiichi-Sankyo, Eli Lilly & Co., Genentech,
Johnson & Johnson, and Novartis. Dr. Mahaffey has received research grants from
Abbott Vascular, Amgen Inc., Amylin Inc., AstraZeneca, Baxter, Bayer Health-
Care, Boehringer Ingelheim, Brisol-Myers Squibb, Cordis, Daiichi Sankyo,From the *Duke Clinical Research Institute, Durham, North Carolina; †Fondazione
IRCCS Policlinico S. Matteo, Pavia, Italy; ‡Green Lane Cardiovascular Service,
Auckland, New Zealand; §Canadian VIGOUR Centre, Edmonton, Alberta, Canada;
TIMI Study Group, Brigham and Women’s Hospital, Harvard Medical School,
Boston, Massachusetts; and the ¶Duke Translational Medicine Institute, Durham,
North Carolina. EARLY-ACS was funded by Schering-Plough, and SYNERGY was
funded by Sanofi-Aventis. The current analyses were funded by Merck, Inc. Dr.
Tricoci has served on an advisory board and has received research grants from Merck,
Inc. Dr. Lopes received a research grant from Bristol-Myers Squibb. Dr. White has
received research grants from Schering-Plough and Merck, Inc. Dr. Armstrong has
received research grants from Schering-Plough Research Institute and Merck, Inc.
Dr. Giugliano is a consultant to Beckman-Coulter; and received research grant
support from Merck. Dr. Antman has received research grants from Eli Lilly &
Edwards Lifesciences, Eli Lilly & Co., GlaxoSmithKline, Guidant Corp., Ikaria,
Johnson & Johnson, KAI, Luitpold Pharmaceuticals, Medtronic, Merck, Inc.,
2297JACC Vol. 60, No. 22, 2012 Leonardi et al.
December 4, 2012:2296–304 Spontaneous Versus Interventional-Related MIThe development of myocardial necrosis after percutaneous
coronary intervention (PCI) consistently is associated with an
increased risk of death, characterized by a direct continuous
relationship between the amount of myonecrosis and the
degree of risk (1–3). These observations support the inclu-
sion of PCI-related myocardial infarction (procedural MI)
along with nonprocedural MI (spontaneous MI) as part of
the MI component of randomized clinical trial endpoints.
However, there is substantial debate regarding whether
procedural and spontaneous MI have similar relationships
with risk for subsequent mortality. The distinction between
spontaneous and procedural MI was a driving force behind
the MI classification proposed by the Universal Definition
of Myocardial Infarction (4), but despite recommendations
made in this consensus document, the 2 types of MI are not
reported separately in most clinical trials (5) and are
weighted equally as endpoints.
Procedural MI typically is defined using creatine
kinase-MB (CK-MB) as the preferred cardiac biomarker,
using an elevation of 3 times the upper limit of normal
(ULN) after the procedure as the diagnostic threshold.
However, the appropriateness of this threshold is disputed
(6–9). Although statistically significant in most studies, the
absolute risk of death associated with procedural MI has
been smaller than that of spontaneous MI (10), prompting
debate regarding the use of procedural MI as a trial
endpoint and whether higher enzymatic thresholds for
procedural MI should be used (7,8).
In the present study, we examined the prognoses of
procedural and spontaneous MI using 2 large contemporary
trials of patients with non–ST-segment elevation (NSTE)
acute coronary syndrome (ACS). By defining procedural MI
using increasing CK-MB thresholds, we compared progno-
ses after procedural MI and after spontaneous MI to
identify an enzymatic threshold for procedural MI that was
associated with 1-year mortality risk similar to that of
spontaneous MI.
Methods
Study population. Patients enrolled in the EARLY-ACS
(Early Glycoprotein IIb/IIIa Inhibition in Non–ST-
Segment Elevation Acute Coronary Syndrome) trial and the
SYNERGY (Superior Yield of the New strategy of Enoxa-
parin, Revascularization and GlYcoprotein IIb/IIIa inhibi-
Novartis, Portola Pharmaceuticals, POZEN Pharmaceuticals, Regado Biosci-
ences, Roche Diagnostic, Schering-Plough, and The Medicines Co.; and is a
consultant for Adolor, Amgen, AstraZeneca, Bayer HealthCare, Biotronik,
Boehringer Ingelheim, Briston-Myers Squibb, Daiichi Sankyo, Eli Lilly & Co.,
Elsevier (AHJ), Exeter Group, Forest, Genentech, GlaxoSmithKline, Gilead
Science, Haemonetics, Johnson & Johnson, Medtronic Inc., Merck & Co.,
Novartis, Orexigen, Orth/McNeill, Pfizer, Polymedix, Sanofi-Aventis, Schering-
Plough, South East Area Health Education Center (SEAHEC), Springer
Publishing, St. Jude Medical, Sun Pharma, and WebMD. All other authors have
reported that they have no relationships relevant to the contents of this paper to
disclose.Manuscript received June 4, 2012; revised manuscript received August 13, 2012,
accepted September 11, 2012.tors) trial (n  19,433) were con-
sidered for analysis (11–14).
Briefly, the EARLY-ACS trial
evaluated the use of early eptifi-
batide in high-risk NSTE ACS
patients for whom an early inva-
sive approach was intended; the
SYNERGY trial compared
enoxaparin with unfractionated
heparin in high-risk NSTE ACS
patients treated with an early inva-
sive strategy. To minimize selec-
tion bias and to include patients at
risk for both types of MI, the
analysis was restricted to subjects
treated with PCI (n  9,087,
46.8%).
Definitions of MI. In both tri-
als, spontaneous and procedural
MI events occurring after ran-
domization and for up to 30 days
after randomization were adjudi-
cated by the same clinical events
classification (CEC) committee, and procedural MI was
defined using similar criteria. Specifically, the enzymatic
criterion for procedural MI required CK-MB levels of 3 or
more times the ULN and an increase of 50% or more from
preprocedural levels if they exceeded ULN. If CK-MB
analysis was unavailable, the CEC committee considered
total creatine kinase, troponin, or new Q waves on electro-
cardiograms. Spontaneous MI definitions also were similar:
each trial used an elevation of cardiac markers of twice the
ULN. However, although CK-MB was favored over tro-
ponin for spontaneous MI in the SYNERGY trial, troponin
or CK-MB could be used in the EARLY-ACS trial. To
account for these differences, we restricted criteria for
spontaneous MI in the EARLY-ACS trial to CK-MB
levels more than twice the ULN (referred to as EARLY-
ACS sMI2) for the combined dataset analyses. The
distinction between spontaneous and procedural MI was
guided by the protocol (Online Appendix). In complex
situations, clinical judgment and agreement between at least
2 clinicians was required to assess MI type.
Statistical analyses. Baseline characteristics and outcomes
were summarized using medians (25th, 75th percentiles) for
continuous variables and percentages for discrete variables.
The primary endpoint was all-cause mortality occurring
from 24 h to 1 year after PCI. The 1-year risks of death
associated with spontaneous and procedural MI were cal-
culated using Cox proportional hazards regression model-
ing. The GRACE (Global Registry of Acute Cardiac
Events) covariates (15) were used for multivariate risk
adjustment. Spontaneous MI was included as a time-
dependent covariate to account for the possibility that this
event could occur throughout the first 30 days of follow-up.
Abbreviations
and Acronyms
ACS  acute coronary
syndrome
CEC  clinical events
classification
CI  confidence interval
CK-MB  creatine kinase-
myocardial band
HR  hazard ratio
MI  myocardial infarction
NSTE  non–ST-segment
elevation
PCI  percutaneous
coronary intervention
sMI2  spontaneous
myocardial infarction in the
EARLY-ACS trial with CK-
MB levels more than twice
the ULN
ULN  upper limit of
normalSpontaneous MI was not collected beyond 30 days in these
1
h
1
i
a
h
i
k
w
7
i
A
t
t
o
c
w
m
t
p
2298 Leonardi et al. JACC Vol. 60, No. 22, 2012
Spontaneous Versus Interventional-Related MI December 4, 2012:2296–304trials. Procedural MI generally was known within 24 h of
PCI (only 3.5% of all procedural MI occurred more than
24 h after PCI) and was included as a fixed baseline
covariate. Adjusted associations of procedural and sponta-
neous MI with 1-year mortality were described using hazard
ratios (HRs) with 95% confidence intervals (CIs).
Associations of spontaneous and procedural MI with
1-year mortality were compared in several ways. First, we
qualitatively compared the risk of death associated with
procedural MI (all CEC-adjudicated events with and with-
out CK-MB levels more than 3 times the ULN) with that
for spontaneous MI in models adjusted for GRACE cova-
riates. Second, to identify a CK-MB threshold for proce-
dural MI at which the adjusted HR for 1-year mortality was
similar to that of spontaneous MI, procedural MI was
redefined using a range of CK-MB peak/ULN thresholds,
increasing from 3 times the ULN in increments of 0.1. If
the ratio exceeded the given threshold value, the subject was
considered to have a procedural MI. For each 0.1 increment,
a new Cox model with GRACE covariates was fitted, and
the resulting HR was compared with that of a spontaneous
MI. The threshold at which the HR for procedural and
spontaneous MI were the same was defined as the matching
threshold. Results were displayed graphically by plotting the
grid of thresholds for the peak-to-ULN ratio against their
corresponding procedural MI HR and connecting the
points. Similarly, confidence bands were plotted using the
corresponding 95% CI for the HR at each grid point; these
represent a plausible range for the risk associated with a
procedural MI defined for the given peak-to-ULN ratio. In
this analysis, the definition of spontaneous MI remained
fixed, with a single HR (plotted as a horizontal line) for
1-year death. A CI for the matching threshold was esti-
mated using an iterative method and was defined as the
0.025 and 0.975 percentiles of the matching thresholds
resulting from analysis of 500 bootstrap replications of the
data and represents a plausible range for the peak-to-ULN
Baseline Characteristics Among Patients With Procedural MI and STable 1 Baseline Characteristics Among Patients With Proced
Procedural MI
(n  773)
Spontaneous MI
(n  239)
Com
Age, yrs 68.8 (61.3–75.0) 69.7 (61.0–76.0)
Male 528 (68.3) 161 (67.4)
Diabetes 214 (27.7) 73 (30.6)
Hypertension 517 (66.9) 158 (66.1)
Current smoker 196 (25.4) 57 (23.9)
Prior MI 214 (27.7) 65 (27.2)
Prior PCI 183 (23.7) 59 (24.7)
Prior chronic HF 67 (8.7) 32 (13.4)
Killip class III or IV 18 (2.3) 3 (1.3)
Baseline CrCl 73.4 (54.9–95.9) 72.9 (54.6–95.9)
GRACE risk 1.82 (1.2–2.8) 1.84 (1.3–2.7)
Elevated cardiac biomarkers 638 (82.5) 203 (84.9)
Values are median (25th to 75th percentile) or n (%). Procedural MI was defined as a clinical even
than 3 times the upper limit of normal. GRACE risk is the probability (of 100%) of in-hospital deaCI confidence interval; CrCl creatinine clearance; EARLY-ACS Early Glycoprotein IIb/IIIa Inhibition i
Events; HF  heart failure; MI  myocardial intervention; PCI  percutaneous coronary intervention.ratio that would result in a procedural MI having the same
risk as a spontaneous MI.
All analyses were performed separately in the SYNERGY
trial and EARLY-ACS trial datasets. Then, after assessing
the consistency of the results, analysis was performed on the
combined dataset, in which the EARLY-ACS trial sMI2
was used to define spontaneous MI. We also performed
sensitivity analyses using a second set of covariates for risk
adjustment and models that included time to PCI and/or
pre-PCI CK-MB level (Online Appendix).
Results
Study population and baseline characteristics. Of the
19,433 total study participants enrolled in the SYNERGY
trial (n  10,027) and the EARLY-ACS trial (n  9,406),
0,259 (52.8%) underwent PCI. Of these, 9,087 (88.6%)
ad complete data and were included in the analysis. Overall
-year mortality was 4.6% (469 deaths). Between random-
zation and 30-day follow-up, 893 procedural MI events
nd 298 spontaneous MI events were adjudicated.
Among 893 patients with procedural MI, 773 (86.6%)
ad CK-MB levels of more than 3 times the ULN and were
ncluded in the analyses; other evidence (total creatine
inase, troponin, or new Q waves on electrocardiograms)
as used in the remaining cases, which were excluded. Of
73 procedural MI defined by CK-MB level, 400 occurred
n the SYNERGY trial and 373 occurred in the EARLY-
CS trial. Of 298 total spontaneous MI, 127 occurred in
he SYNERGY trial and 171 occurred in the EARLY-ACS
rial. The median (25th, 75th) time from PCI to spontane-
us MI was 2 days (interquartile range: 1 to 5 days) in the
ombined dataset. Among the EARLY-ACS trial patients
ith spontaneous MI, 112 (65.5%) had CK-MB levels of
ore than twice the ULN (EARLY-ACS sMI2). Thus,
he combined patient set used for analysis included 773
rocedural MI and 239 spontaneous MI. A total of 28
aneous MI and Overall PCI PatientsI and Spontaneous MI and Overall PCI Patients
PCI Population
10,259)
SYNERGY PCI Population
(n  4,700)
EARLY-ACS PCI Population
(n  5,559)
(59.3–74.0) 67.0 (60.0–74.0) 66.7 (59.0–74.4)
(70.1) 3,225 (68.6) 3,968 (71.3)
(27.7) 1,238 (26.3) 1,607 (28.9)
(67.1) 3,082 (65.6) 3,803 (68.4)
(20.4) 1,272 (27.1) 1,635 (29.4)
(26.3) 1,230 (26.2) 1,463 (26.3)
(23.5) 1,004 (21.4) 1,409 (25.3)
(8.7) 317 (6.7) 575 (10.3)
(1.8) 85 (1.8) 93 (1.7)
(59.1–100.7) 79.1 (60.5–101.6) 76.8 (57.9–99.7)
(1.7–2.6) 1.57 (1.11–2.34) 1.81 (1.22–2.83)
(81.8) 3,955 (84.1) 4,436 (79.9)
ification committee–adjudicated peri-PCI MI with creatine kinase-myocardial band levels of more
d on GRACE risk score. Baseline CrCl is creatinine clearance at admission.pontural M
bined
(n 
66.9
7,193
2,845
6,855
2,907
2,693
2,413
892
178
77.9
1.68
8,391
ts class
th basen Non–ST-Segment Elevation Acute Coronary Syndrome; GRACEGlobal Registry of Acute Cardiac
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December 4, 2012:2296–304 Spontaneous Versus Interventional-Related MI(0.27%) patients had both PCI-related and spontaneous MI
and were included in both model analyses. Baseline char-
acteristics are shown in Table 1.
Association of spontaneous and procedural MI with
1-year mortality. After risk adjustment, spontaneous MI
had an HR for death at 1 year of 7.35 (95% CI: 4.88 to
Figure 1 Hazard Ratio Plots of Definitions of Procedural Myoca
Hazard ratio (HR) plots for (top) all clinical events classification (CEC)-adjudicated
tine kinase-myocardial band (CK-MB) level of more than 3 times the upper limit of
3 times the ULN, but with other evidence (120 events). CI  confidence interval; E
Coronary Syndrome; SYNERGY  Superior Yield of the New strategy of Enoxaparin11.06) in the SYNERGY trial, 4.42 (95% CI: 2.90 to 6.74)in the EARLY-ACS trial using the original definition, and
3.61 (95% CI: 2.15 to 6.08) using the EARLY-ACS trial
sMI2 definition compared with patients with no sponta-
neous MI. The HR for patients with procedural MI
compared with those without was 1.45 (95% CI: 0.93 to
2.25) in the SYNERGY trial and 1.34 (95% CI: 0.89 to
Infarction
ural MI (893 events), (middle) procedural myocardial infarction (MI) with crea-
l (ULN; 773 events), and (bottom) procedural MI without CK-MB level more than
-ACS  Early Glycoprotein IIb/IIIa Inhibition in Non–ST-Segment Elevation Acute
scularization and GlYcoprotein IIb/IIIa inhibitors.rdial
proced
norma
ARLY
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MI using any criterion (all CEC-adjudicated procedural
MI) or a combination of criteria but no CK-MB value of
more than 3 times the ULN (other evidence) was similar to
that for procedural MI adjudicated with CK-MB levels
more than 3 times the ULN alone (Fig. 1). However, the
HR for CEC-adjudicated MI that used other evidence
varied more by individual trial than did the HR of
procedural MI determined with CK-MB levels of more
than 3 times the ULN. In the combined analyses, the risk
of death associated with spontaneous MI was 5.37 (95%
CI: 3.90 to 7.38) and 1.38 (95% CI: 1.01 to 1.89) for
procedural MI.
Effect of varying CK-MB threshold for procedural MI on
relationship with 1-year mortality. Figure 2 presents the
istribution of peak CK-MB indexed by ULN for sponta-
eous and procedural MI events. In general, peak CK-MB
levations for spontaneous MI were lower and were associ-
ted with a heavier weight in the lower tail of the distribu-
ion than procedural MI, suggesting that spontaneous MI
ere adjudicated more often with lower CK-MB peak than
rocedural MI. Figure 3 presents the grid search over
ifferent CK-MB thresholds for defining procedural MI
n the combined dataset. By increasing the CK-MB
hreshold for procedural MI, a corresponding continuous
ncrease was observed in the HR for 1-year death, which
as more evident at low thresholds. The threshold at
hich the HR of procedural MI with 1-year mortality
rst matched that of spontaneous MI was 57.9 times the
LN in the SYNERGY trial, 20.4 times the ULN in the
Figure 2 Distribution of Peak CK-MB Values
for Spontaneous and Procedural MI
Density distribution of CEC-adjudicated peak CK-MB values indexed by
ULN value for spontaneous and procedural MI. Abbreviations as in Figure 1.ARLY-ACS trial with the spontaneous MI definitionsed by the CEC committee, and 17.7 times the ULN in
he EARLY-ACS trial with the sMI2 definition (Table 2).
n the combined dataset, the matching threshold was 27.7
imes the ULN (95% CI: 13.9 to 58.4). At this enzymatic
hreshold, there were only 49 (6%) procedural MI events
Fig. 4).
ensitivity analyses. After risk adjustment with SYNERGY
rial covariates instead of GRACE covariates, matching
hresholds for procedural MI were lower but consistently
arger than 3 times the ULN (Online Table). Similar
esults also were found when adjusting for the time to
CI and CK-MB level before PCI in addition to the
linical model.
iscussion
n a large population of patients with NSTE ACS, proce-
ural MI was more common but associated less strongly
ith death at 1 year than spontaneous MI. A higher
nzymatic threshold for procedural MI was needed to match
he prognosis of spontaneous MI, and although the estimate
aried between the SYNERGY trial and the EARLY-ACS
rial, the CI for the matching threshold showed substantial
verlap between groups.
In addition, the estimates were characterized by broad CI
13.9 to 58.4 for combined data), because only a small
ortion of patients with procedural MI exhibited elevations
Figure 3 CK-MB Threshold Analysis for Procedural MI
Solid red line represents the HR point estimate for 1-year death of spontane-
ous MI. Dotted red lines are corresponding 95% CI. The solid blue line repre-
sents the HR for 1-year, death and the dotted blue lines are the 95% CI of
procedural MI defined by increasing CK-MB peak-to-ULN ratios. This line was
created by connecting the dots for every 0.10 increase of the CK-MB level
threshold (i.e., each grid point). The CK-MB level threshold that achieved a
prognosis similar to spontaneous MI (i.e., matching HR) was 27.7 in the com-
bined data set (using EARLY-ACS trial with CK-MB levels more than twice the
ULN definition). Abbreviations as in Figure 1.
EARLY-
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December 4, 2012:2296–304 Spontaneous Versus Interventional-Related MIof CK-MB levels this extreme. Despite the large popula-
tion, precisely estimating the matching threshold was chal-
lenging and will require further refinement in larger data-
sets. The relevant intratrial and intertrial variability in the
matching threshold calls for caution when extrapolating
these results to other settings. Nevertheless, these data
provide evidence that for the 1-year mortality risk for
procedural MI to reach a level similar to that of spontaneous
MI, an elevation of CK-MB level of more than 3 times the
ULN is required. A conservative estimate based on the
lower bound of the 95% CI in our combined dataset
suggests a threshold of nearly 14 times the ULN may be
required. However, based on results in the EARLY-ACS
trial dataset, in which the hazard of death associated with
spontaneous MI with subsequent mortality was less strong, the
estimated threshold could be as low as 5 times the ULN.
Separate reporting of MI types and infarct size reporting.
The more favorable prognosis observed after procedural MI
(CK-MB more than 3 times the ULN) compared with that
after spontaneous MI has been reported (10). The concor-
Matching Thresholds in Different DatasetsTable 2 Matching Thresholds in Different Da
Dataset
HR (95% CI) of
Spontaneous MI
Match
Thresh
SYNERGY 7.35 (4.88–11.06) 57.9
EARLY-ACS 4.42 (2.90–6.74) 20.4
EARLY-ACS (sMI2) 3.61 (2.15–6.08) 17.7
Combined 5.37 (3.90–7.38) 27.7
HR hazard ratio; sMI2 spontaneous myocardial infarction in the
the ULN; other abbreviations as in Table 1.
Figure 4 Cumulative Reduction of
Procedural MI for Increasing CK-MB Thresholds
The starting point with 100% of procedural MI included 773 events. At the
prognostically similar threshold for the combined dataset (27.7 times the ULN),
only 49 procedural MI events were present (6.3% of total).dance of the present findings with previous observations
supports the Universal Definition of Myocardial Infarction
Task Force’s recommendation for separate reporting of the
effects of intervention on each type of MI (4). This group
also recommends reporting the effect of experimental treat-
ments using higher biomarker thresholds for procedural MI
(i.e., 5 times the ULN and 10 times the ULN) and, ideally,
the total distribution of biomarkers values. Both recommen-
dations have been implemented only sporadically across
clinical trials (5).
The higher risk of 1-year mortality associated with
increasing CK-MB levels after procedural MI also provides
a solid rationale for reporting infarct size in clinical trials.
Regardless of the specific definition chosen for procedural
MI, the availability of the complete biomarker dataset
would permit more comprehensive exploration of the effects
of interventions.
Differential weighting of procedural MI defined by
increasing enzymatic thresholds in composite endpoints.
Although small elevations in CK-MB levels occurring after
PCI still may be clinically relevant and worth preventing,
combining nonfatal endpoints with unequal associations
with outcomes poses interpretative challenges when assess-
ing the effects of interventions. Although death is the key
component of a composite clinical outcome, the use of
composite endpoints that associate death with nonfatal
events is predicated on the assumption that nonfatal com-
ponents are of similar clinical importance, and common
statistical approaches use equal weights for individual com-
ponents of a composite endpoint (16–18). Importantly,
more than three–quarters of the endpoint MI across both
trials were procedural MI. Prognostic homogeneity there-
fore is a key property of nonfatal end point components, but
this is rarely achieved (19), and attempts have been made to
refine composite outcomes by developing novel approaches
that include weighted individual components (20) or attrib-
utable risk (21).
We focused on prognostic homogeneity between MI
components to reassess the diagnostic threshold for proce-
dural MI. By using increasing levels of CK-MB elevation
after PCI, our interest was to emphasize the degree of
mortality risk over the precision of its estimate. Because of
the rapid reduction of procedural MI events with increasing
CK-MB level threshold, we observed increasing HR but
ts
95% Bootstrap CI for
Matching Threshold
n (%) of Procedural MI
at Matching Threshold
17.9–63.6 15 (4)
5.2–24.2 71 (19)
4.1–23.9 94 (25)
13.9–58.4 49 (6)
ACS trial with creatine kinase-myocardial band levels more than twicetase
ing
oldbroader CI and, eventually, opposite effects on statistical
2302 Leonardi et al. JACC Vol. 60, No. 22, 2012
Spontaneous Versus Interventional-Related MI December 4, 2012:2296–304significance. This suggests that an enzymatic definition for
procedural MI that relies solely on statistical significance
may not account fully for the prognostic implications of a
procedural MI.
The composite of procedural and spontaneous MI is a
combination of heterogeneous events with substantially
different prognoses. This is of particular concern for inter-
ventions that are expected to have unequal effects on
spontaneous MI or procedural MI, such as early invasive
strategy compared with conservative management in pa-
tients with NSTE ACS (22,23). In this situation, a positive
effect on spontaneous MI associated with early invasive
strategy could be obscured by more common but less
prognostically relevant procedural MI. This suggests a need
for separate analysis by differentially weighting effects of
experimental treatments on these MI endpoints, or alterna-
tively, considering the use of higher degrees of CK-MB
elevation for procedural MI.
Interestingly, 2 recent analyses assessing the prognostic
significance of spontaneous and procedural MI (24,25) have
demonstrated a similar discrepancy between the prognoses
of procedural and spontaneous MI. This may be related to
the different cardiac marker thresholds used to define
procedural MI. In 1 analysis (24), in which no association
was observed, procedural MI was defined by a cardiac
marker threshold between once and twice the ULN, similar
to that used for spontaneous MI; whereas in the TRITON–
TIMI 38 (Trial to Assess Improvement in Therapeutic
Outcomes by Optimizing Platelet Inhibition With Prasugrel–
Thrombolysis in Myocardial Infarction 38) trial (25), in
which procedural MI was associated with a significant
2-fold increase in the risk of death (adjusted HR: 2.4, 95%
CI: 1.6 to 3.7, p  0.001), the cardiac marker threshold
used for procedural MI was between 3 times the ULN and
5 times the ULN. Our present analysis provides a link
between these varying definitions by evaluating a full spec-
trum of candidate thresholds.
The main analytical advantage offered by composite
outcomes is the increase in statistical efficiency provided by
a greater number of end points (26). Although maximizing
prognostic homogeneity is desirable, the substantial reduc-
tion of procedural MI events observed with increasing
enzymatic thresholds poses logistical challenges, such as
increased sample size and/or study duration. In the present
analysis, this attenuation of events with increasing thresh-
olds for CK-MB level corresponds to substantial variability
in the estimated matching threshold. However, in our
combined analysis, even the lower bound for the matching
threshold was 13.9 times the ULN. The ideal threshold should
balance the competing objectives of prognostic homogeneity,
clinical relevance, and maximizing endpoints.
Is myocardial damage worse for spontaneous MI than for
procedural MI? Finally, it is unclear why similar levels of
CK-MB elevation were associated with different levels of risk
in the setting of procedural versus spontaneous MI. It is
possible that myonecrosis caused by PCI is truly more benigncompared with spontaneous MI events and coronary revascu-
larization, and/or that other periprocedural treatments may
have other benefits that attenuate the association between
amount of periprocedural myonecrosis and mortality.
The possibility of a differential detection of true peak
CK-MB levels between spontaneous and procedural MI
also should be considered. Although time of onset for
procedural MI can be known precisely, the best surrogate we
have for spontaneous MI is the time of onset of symptoms,
and it is common for patients with NSTE ACS to defer
seeking medical attention for hours or days after symptoms
emerge. Hence, the observed difference in prognosis be-
tween the 2 types of MI may be influenced by ascertainment
bias.
Study limitations. First, the enzymatic definition for spon-
taneous MI used (CK-MB more than twice the ULN) is
higher than current recommendations. The Universal Def-
inition of Myocardial Infarction, developed after both stud-
ies were designed, recommends an elevation of once the
ULN and designates troponin and not CK-MB as the
preferred biomarker (4). Although a higher threshold may
have increased the observed strength of association of
spontaneous MI with subsequent outcome, recent evidence
suggests that minor troponin elevation (just higher than the
ULN) is associated with worse prognosis than even higher
levels (27). Interestingly, the inclusion of every spontaneous
MI in the EARLY-ACS trial (including events with a
CK-MB of less than twice the ULN) was associated with a
higher risk of mortality; other authors who used troponin
elevation above the ULN to define spontaneous MI found a
higher HR for death compared with our analysis (10). Thus, it
remains unclear whether (and if so, how) a different definition
of spontaneous MI could have affected our results.
Second, it is impossible to define a single matching
threshold; slight differences in populations and covariates
induce inherent heterogeneity. In particular, the risk asso-
ciated with spontaneous MI (especially among patients receiv-
ing medical management because of coronary anatomical
features judged unsuitable for PCI) (28,29) may differ
from that of a procedural MI. Although residual con-
founding cannot be excluded, the analysis population was
restricted to patients who actually underwent PCI, and
analyses were adjusted to minimize selection bias and
measured confounders.
Third, in patients undergoing very early PCI, the dis-
crimination between the procedural MI endpoint and the
qualifying, spontaneous MI may be challenging because of
increasing biomarkers at the time of PCI. However, the
median time from admission to PCI was 21 hours in the
SYNERGY trial, and the EARLY-ACS trial included only
patients expected to undergo an invasive strategy no sooner
than the next calendar day after randomization. Thus, it
seems unlikely that a significant proportion of patients had
increasing markers before PCI. Also, we used procedural
MI adjudicated by at least 2 experienced CEC committee
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covariate in the model for risk adjustment.
Fourth, there are different MI locations and subtypes of
spontaneous MI (ST-segment elevation vs. non–ST-
segment elevation) and procedural MI (11). Part of the
damage induced by PCI is unavoidable and is unlikely to be
affected by antithrombotic or other therapies. A bio-
marker elevation may have a different association with
mortality in the presence of an overt clinical syndrome or
a clear angiographic complication. However, these dis-
tinctions are not well standardized and were not captured
consistently across the 2 trials we examined. Thus, the
present analysis is an appropriate comparison of proce-
dural and spontaneous MI, as defined by trials, but does
not necessarily extrapolate to clinical events that involve
additional information.
Fifth, study follow-up was limited to 1 year. Longer
follow-up could have provided different results.
Finally, there is no unique gold standard for defining the
relationship of procedural MI with outcome or for ascer-
taining how that differs from spontaneous MI. Although other
approaches can complement ours (e.g., maximal discrimina-
tion, maximal predictive ability), we believe that the emphasis
on prognostic homogeneity can highlight an additional dimen-
sion for the definition of this endpoint.
Conclusions
Spontaneous MI (CK-MB levels more than twice the
ULN) is associated strongly with death at 1 year. Using the
enzymatic definition of CK-MB levels more than 3 times
the ULN, procedural MI was associated more weakly with
1-year death. A higher CK-MB level threshold for proce-
dural MI would be needed to reach an association of
procedural MI with 1-year mortality similar to that of
spontaneous MI. These observations raise implications for
the design and interpretation of clinical trials that use MI as
an endpoint.
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APPENDIX
For more detailed definitions of endpoint myocardial infarction and sensi-
tivity analyses as well as a supplemental table, please see the online
version of this article.
